Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Representative Results
  • Discussion
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

Presented here is a protocol to show that Bazi Bushen capsule (BZBS) can regulate the RANKL/OPG signaling pathway in the ovariectomized rodent model through its estrogen-like effect.

Abstract

This study aims to show the estrogen-like effect of Bazi Bushen capsule (BZBS), a Chinese herbal compound, in ovariectomized mice. Female Sprague-Dawley (SD) rats were randomly divided into six groups: a sham-operated group, a model group (OVX), a progynova group, and BZBS groups (1, 2, and 4 d/kg/d). An ovariectomy was performed on all rats except those in the sham-operated group. Micro-computed tomography (micro-CT) scanning, hematoxylin and eosin (H&E) staining, immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA) detection were performed after 4 months of BZBS treatment. As a result, compared with the OVX group, rats treated with BZBS showed an increased number and area of trabecular bone and bone marrow cells, and a decreased number of adipose cells. The bone volume, trabecular number, and trabecular thickness of the right tibia in the medication groups increased and the trabecular space decreased. The 17β-estradiol and serum calcium levels in the medication groups were elevated, but the levels of serum phosphorus, sclerostin, β-CTX, and TRACP-5b were decreased. In the medication groups, the RANKL and sclerostin levels were decreased, while the osteoprotegerin (OPG) level was increased. In conclusion, this protocol systematically evaluated the therapeutic effects and potential molecular mechanisms of Chinese herbal compounds in ovariectomized rats with a variety of techniques.

Introduction

Postmenopausal osteoporosis (PMOP) is a skeletal system disease caused by inadequate ovarian function, decreased estrogen, and enhanced osteoclast activity1, characterized by low bone mass, microarchitectural degeneration of the bone tissue, and damage of the bone trabecula. PMOP prone to cause fractures and can have serious effects on patients' quality of life. Osteoporosis affects about 200 million people worldwide2; about 40% of postmenopausal women suffer from osteoporosis3, and fractures occur in 33% of patients with PMOP4. The reduction of estrogen could lead to a rel....

Protocol

The animal experiments were approved by the Committee on Animal Research and Ethics of the Hebei Yiling Medical Research Institute (approval number: N2020150). The 36 Sprague-Dawley (SD) female rats (3 months old, weighing 180-200 g) (see Table of Materials) were fed with normal food and clean water in the new drug evaluation center of Hebei Yiling Medical Research Institute and were exposed to artificial light for 12 h per day in rooms with controlled temperatures (20-26 °C) and relative humidity (.......

Representative Results

The bone microstructure of the tibia was evaluated by micro-CT scanning
The treatment of ovariectomized rats with BZBS significantly reduced OVX-induced trabecular structural changes. As shown in the reconstructed micro-CT images of the right tibia (Figure 1A,B), trabecular bone in the OVX group showed a significant decrease in BMD (Figure 1C), BV/TV (Figure 1D), Tb.Th (Fi.......

Discussion

After ovariectomy, estrogen levels decreased sharply due to the continuous reduction of cancellous bone and increased bone turnover. Essentially, decreased estrogen secretion after menopause could cause significant bone loss18, leading to Ca2+ loss in ovariectomized rats19,20. It has been reported that taking estrogen can help the metaphyseal fracture recovery of ovariectomized rats, and estrogen replacement therapy can also be .......

Acknowledgements

This work was supported by the Strategic Consulting Project of the Chinese Academy of Engineering: Strategic research on anti-aging effect of Traditional Chinese Medicine (Grant No.: 2022-XY-45), the Natural Science Foundation of Hebei Province in China (Grant No.:2022106065), S&T Program of Hebei, China (Grant No.:22372502D) and High-level S&T Innovation and Entrepreneurship Talent Project of Shijiazhuang, Hebei, China (Grant No.: 07202203).

....

Materials

NameCompanyCatalog NumberComments
10% neutral buffered formalinProteintech Group, Inc.23408-1AP-100
17-Beta-Estradiol ELISA kitsProteintech Group, Inc.21933-1-AP
3%H2O2ShanDong LIRCON Medical Technology Incorporated Company20221027
Anti-osteoprotegerin antibodyAbcamab203061
Bazibushen capsulesShijiazhuang Yiling Pharmaceutical Co. Ltd.XB2103001
Biotin goat anti-rabbit IgGAbcamab207995
Calcium assay kitsNanjing Jiancheng Bioengineering InstituteC004-2-1
DiaminobenzidineZSGB-BIOZLI-9018
Estradiol valerate tabletsBayer AG156A
Gene 1580R centrifugeGENE Co. Ltd. GZ422515090077
Image-Pro PlusMedia CyberneticsIPP 6.0
Leica DM6000B Microscope (fully automated upright microscope system)Leica361715
Normal Goat Serum Blocking SolutionVector LaboratoriesS-1000-20
Phosphate assay kitsNanjing Jiancheng Bioengineering InstituteC006-1-1
Phosphate buffered salineServicebio, Wuhan, ChinaCR10201M
Quantum GX2 microCT Imaging SystemPerkinElmerCLS149276
RANKL rabbit polyclonal antibodyElabscience Biotechnology Co. Ltd.E-EL-R3032-96T
Rat SOST (Sclerostin) ELISA kitElabscience Biotechnology Co. Ltd.E-EL-R1405c-96T
Rat TRACP-5b (Tartrate Resistant Acid Phosphatase 5b) ELISA kitAbcamab108667
Rat β-CTx (Beta Crosslaps) ELISA kitElabscience Biotechnology Co., Ltd.E-EL-R0939c-96T
Sclerostin rabbit polyclonal antibodyBeijing Vital River Laboratory Animal Technology Co., Ltd.SCXK(JING)2016-0006
Slide scannerHamamatsu Photonics K.K.Nano Zoomer-SQ
Sprague Dawley female ratsBeijing Vital River Laboratory Animal Technology Co., Ltd.ZLI-9381

References

Explore More Articles

MedicineEstrogen like EffectTrabecular BoneBone Marrow CellsAdipose Cells17 estradiolSclerostinRANKLOPG

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved